Next-generation weight-loss pills could hit the market in the coming months, with new data raising a key question: Will patients embrace a more convenient alternative to injecting themselves, even if it means losing less weight?

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists developed causes people who are overweight or obese, but not d